Bronchiectasis Clinical Trial Pipeline Expands as 15+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | AstraZeneca, Insmed, Boehringer Ingelheim, CSL, RedHill, Chies

DelveInsight's "Bronchiectasis - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies, including AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others developing 15+ pipeline drugs in the Bronchiectasis pipeline landscape.
DelveInsight's "Bronchiectasis - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies developing 15+ pipeline drugs in the Bronchiectasis pipeline landscape. It covers the Bronchiectasis pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Bronchiectasis treatment landscape. Learn more about the evolving Bronchiectasis pipeline today @ https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Bronchiectasis Pipeline Report

*
In August 2025, FDA approves brensocatib (Brinsupri) as the first and only treatment for adult patients with NCFB bronchiectasis, based on ASPEN trial data showing reduced exacerbations.

*
In July 2025, Boehringer Ingelheim announces a study for BI 1291583 in bronchiectasis patients.

*
In April 2025, Phase 3 ASPEN trial results for brensocatib published, confirming significant reduction in pulmonary exacerbations and slower lung function decline in NCFB patients.

*
DelveInsight's Bronchiectasis Pipeline Insight report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Bronchiectasis treatment.

*
The leading Bronchiectasis companies include AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others.

*
Promising Bronchiectasis therapies include S1226, Brensocatib, NP339, CHF 6333, CSL787, HSK31858, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, Ensifentrine, Itepekimab and others.

Download for updates and the latest revolution in Bronchiectasis care @ Ovarian Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Bronchiectasis Emerging Drugs Profile

*
Benralizumab: AstraZeneca

Benralizumab is a monoclonal antibody used to treat eosinophilic asthma. It is a humanized recombinant monoclonal antibody of the isotype IgG1 immunoglobulin that specifically binds to the alpha chain of the interleukin5 receptor (IL5R) expressed on eosinophils and basophils, leading to targeted depletion of these cells. Benralizumab is currently being evaluated in a Phase III clinical trial to treat noncystic fibrosis Bronchiectasis.

*
S1226: SolAeroMed

S1226 is a formulation consisting of aerosolized carbon dioxide (CO) and nebulized perflubron delivered into the lung. The delivery of this formulation results in an immediate relaxant effect on constricted airways, supported by lowering of surface tension in inflamed areas and possible clearing of mucus plugs, providing a unique physiologic and biophysical approach to relieving airway obstruction. CO acts as a potent, shortacting bronchial smoothmuscle relaxant, while perflubron is a biocompatible perfluorocarbon with mucolytic and surfactant properties that synergize with CO to enhance and prolong bronchodilation.

For more information on the Bronchiectasis Emerging Drugs Profile, download DelveInsight's comprehensive Bronchiectasis Pipeline Insight report [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The Bronchiectasis Pipeline Report Provides

*
Detailed insights about companies developing therapies for Bronchiectasis, with aggregate therapies developed by each company.

*
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Bronchiectasis treatment.

*
Bronchiectasis companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Bronchiectasis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Bronchiectasis market.

Learn more about Bronchiectasis Drugs opportunities in our comprehesive Bronchiectasis pipeline report @ Bronchiectasis Unmet Needs [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Bronchiectasis Companies

There are 15+ key companies, such as AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others, developing therapies for Bronchiectasis, with AstraZeneca having its Bronchiectasis drug candidate in the most advanced Phase III stage.

DelveInsight's Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

*
Intranasal

*
Intravenous

*
Subcutaneous

*
Oral

*
Parenteral

Bronchiectasis products have been categorized under various Molecule types such as:

*
Antibody

*
Antisense oligonucleotides

*
Immunotherapy

*
Monoclonal antibody

*
Peptides

*
Protein

*
Recombinant protein

*
Small molecule

*
Stem Cell

*
Vaccine

Discover the latest advancements in Bronchiectasis treatment by visiting our website. Stay informed @ Bronchiectasis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Scope of the Bronchiectasis Pipeline Report

*
Coverage: Global

*
Bronchiectasis companies: AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others

*
Bronchiectasis Therapies: S1226, Brensocatib, NP339, CHF 6333, CSL787, HSK31858, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, Ensifentrine, Itepekimab and others.

*
Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

*
Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Preclinical, Phase I, Phase II, Phase III

Table of Contents

*
Introduction

*
Executive Summary

*
Bronchiectasis: Overview

*
Pipeline Therapeutics

*
Therapeutic Assessment

*
Bronchiectasis - DelveInsight's Analytical Perspective

*
Late Stage Products (Phase III)

*
Mid Stage Products (Phase II)

*
Early Stage Products (Phase I)

*
Preclinical and Discovery Stage Products

*
Inactive Products

*
Bronchiectasis Key Companies

*
Bronchiectasis Key Products

*
Bronchiectasis Unmet Needs

*
Bronchiectasis Market Drivers and Barriers

*
Bronchiectasis Future Perspectives and Conclusion

*
Bronchiectasis Analyst Views

*
Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchiectasis-clinical-trial-pipeline-expands-as-15-pharma-companies-progress-novel-therapies-toward-market-entry-finds-delveinsight-astrazeneca-insmed-boehringer-ingelheim-csl-redhill-chies]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.